AB&B BIO-TECH-B (02627) and Hong Kong Watson have entered into a strategic partnership agreement for the expansion of the overseas market for subunit influenza vaccines.

AB&B BIO-TECH-B (02627) announced that the company has signed a strategic cooperation agreement with Walvax Biotechnology Hong Kong Limited (Hong Kong Watson) regarding the overseas market expansion of its subsidiary influenza vaccine. According to the agreement, both parties will collaborate deeply on the overseas market registration, sales, and commercialization of the group's research and development products. The core product of this overseas expansion is the trivalent subunit influenza vaccine (Whelcynex 3) developed independently by the group. The product was approved for listing in January 2026 and is the first and only trivalent subunit influenza vaccine in China suitable for the entire population aged six months and above. The board believes that Hong Kong Watson is a pioneer in overseas business expansion with rich experience in international operations. Through this cooperation, the company will leverage the overseas market resources and mature distribution network accumulated by Hong Kong Watson over many years to accelerate the entry of products into markets in Southeast Asia, Latin America, the Middle East, and other regions in the Southern Hemisphere.